Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 49
Filter
1.
Am J Reprod Immunol ; 88(5): e13620, 2022 11.
Article in English | MEDLINE | ID: mdl-36148557

ABSTRACT

PROBLEM: It is important to evaluate the dynamics of uterine natural killer (uNK) cells in hormone replacement therapy (HRT) cycles, given their potential role in implantation and the common usage of HRT cycles with in vitro fertilization (IVF). METHOD OF STUDY: A total of 132 subfertile patients were evaluated during the secretory phase of either natural ovulation (OV) or HRT cycles, with two biopsies taken on approximately days 5 and 10 after ovulation/progesterone administration in a single menstrual cycle. Immunohistochemical Personal Endometrial Maturation Analysis (PEMA) was used to better quantify secretory-phase endometrial development, in combination with subsequent evaluation of uNK cell density. RESULTS: uNK cell density increased rapidly from the early to mid-secretory phase, with mean uNK densities of 113 and 117 per mm2 in first biopsies and 315 and 387 per mm2 in second biopsies for OV and HRT cycles, respectively. After reassessment of endometrial development with PEMA, the first and second biopsies in HRT and OV cycles were histologically dated to developmental ranges between days 15-20 (first biopsy) and days 19-25 (second biopsy). CONCLUSION: Subfertile women showed variable endometrial development in PEMA assessment, with uNK cell density correlating with the dating results. Overall, comparable levels of uNK cell density were observed in OV and HRT cycles. Importantly, uNK cell density depends on the histological maturation stage, with similar low coefficients of determination. This observation suggests that aberrant uNK cell results more likely reflect displaced endometrial maturation, rather than an intrinsic anomaly in uNK cell trafficking.


Subject(s)
Embryo Implantation , Endometrium , Female , Humans , Endometrium/pathology , Uterus , Killer Cells, Natural/pathology , Fertilization in Vitro
2.
Sci Rep ; 12(1): 1911, 2022 02 03.
Article in English | MEDLINE | ID: mdl-35115587

ABSTRACT

Many critical advances in research utilize techniques that combine high-resolution with high-content characterization at the single cell level. We introduce the MICS (MACSima Imaging Cyclic Staining) technology, which enables the immunofluorescent imaging of hundreds of protein targets across a single specimen at subcellular resolution. MICS is based on cycles of staining, imaging, and erasure, using photobleaching of fluorescent labels of recombinant antibodies (REAfinity Antibodies), or release of antibodies (REAlease Antibodies) or their labels (REAdye_lease Antibodies). Multimarker analysis can identify potential targets for immune therapy against solid tumors. With MICS we analysed human glioblastoma, ovarian and pancreatic carcinoma, and 16 healthy tissues, identifying the pair EPCAM/THY1 as a potential target for chimeric antigen receptor (CAR) T cell therapy for ovarian carcinoma. Using an Adapter CAR T cell approach, we show selective killing of cells only if both markers are expressed. MICS represents a new high-content microscopy methodology widely applicable for personalized medicine.


Subject(s)
Biomarkers, Tumor/metabolism , Epithelial Cell Adhesion Molecule/metabolism , Fluorescent Antibody Technique , Immunotherapy, Adoptive , Neoplasms/metabolism , Neoplasms/therapy , Photobleaching , Single-Cell Analysis , Thy-1 Antigens/metabolism , Cell Death , Cytotoxicity, Immunologic , High-Throughput Screening Assays , Humans , Neoplasms/immunology , Neoplasms/pathology , Receptors, Chimeric Antigen/genetics , Receptors, Chimeric Antigen/metabolism , T-Lymphocytes/immunology , T-Lymphocytes/metabolism , T-Lymphocytes/transplantation
3.
Sci Rep ; 11(1): 20642, 2021 10 19.
Article in English | MEDLINE | ID: mdl-34667243

ABSTRACT

The variable brightness of the night sky affects plants as well as animals and humans. However, knowledge about this variability is still insufficient. Outstanding questions regarding how significant the influence of the moon, clouds, and artificial lighting remain. To be able to make statements about these effects, measurements over a long period of time are necessary. Fraunhofer IOSB performs such measurements in the 380-780 nm photopic visual and 800-1700 nm shortwave infrared spectral range. As the latter is only marginally affected by artificial lighting, a comparison of the two bands deepens insight into the influence of artificial lighting. First analyses show that the moon is, as expected, the dominant light source in the night sky, especially during a full moon. Illuminance values up to 200 mlx and irradiance values up to 600 µW/m2 were measured in the visible and infrared respectively. The influence of clouds is more complicated. The measured intensities depend, among other things, on cloud cover and cloud altitude. When the night sky is overcast, the measured intensities can drop as low as 0.5 mlx and 0.5 µW/m2, respectively. These small values were measured during rainfall. The influence of artificial illumination is difficult to estimate, as intensities in the shortwave infrared decrease with increasing cloud cover, but increase in the visual.

4.
Arch Gynecol Obstet ; 304(6): 1599-1609, 2021 12.
Article in English | MEDLINE | ID: mdl-34009460

ABSTRACT

PURPOSE: Limited information is clinically available concerning endometrial receptivity; assessing endometrial transformation status is therefore an urgent topic in assisted reproductive technology. This study aimed to investigate individual endometrial transformation rates during the secretory phase in subfertile patients using personal endometrial transformation analysis. METHODS: Monitoring was carried out during the secretory phase to obtain endometrial receptivity profiles. For the investigation, two endometrial biopsies were taken within one menstrual cycle. The extended endometrial dating was based on the Noyes criteria, combined with immunohistochemical analyses of hormone receptors and proliferation marker Ki-67. Biopsies were taken mainly at days ovulation (OV, n = 76)/hormone replacement therapy (HRT, n = 58) + 5 and + 10. RESULTS: The results of the two biopsies were correlated with the clinically expected day of the cycle and showed temporal delays or hypercompensations, diverging from the expected cycle days by 0.5-5 days. In comparison with the first biopsies, the transformation rate in the second biopsies showed compensation, augmented delay, or constant transformation in 48.69, 22.37, and 28.94% of cases for ovulation in natural cycles and 56.89, 25.85, and 17.26% for HRT cycles, respectively. CONCLUSION: The study revealed an individually dynamic transformation process of the endometrium, with the ability to compensate or enlarge an initial "delay", which is now identified as a normal individual transformation process during the secretory phase. This information is of great importance for the scientific investigation of dynamic changes in endometrial tissue, as well as for the timing of embryo transfers.


Subject(s)
Embryo Implantation , Endometrium , Embryo Transfer , Female , Humans , Menstrual Cycle , Ovulation
5.
In Vivo ; 34(4): 1951-1963, 2020.
Article in English | MEDLINE | ID: mdl-32606167

ABSTRACT

BACKGROUND/AIM: This study assessed whether a new immunohistochemical dating method allows precise endometrial dating allowing optimal timing for embryo transfer. PATIENTS AND METHODS: A novel method was used for endometrial dating, with parameters including menstrual cycle days, Noyes histological criteria, along with immunohistochemical expression pattern of estrogen and progesterone receptors and proliferation marker Ki-67. Endometrial maturation was analyzed on days +5 to +10 after ovulation or progesterone administration in 217 biopsies from 151 subfertile patients during the secretory phase. RESULTS: Endometrial maturation varied individually, occurring 1.68±1.67 days late. Comparison of histological maturation with clinical days after ovulation showed a delay of about 2 days. CONCLUSION: Endometrial maturation requires 8 days, rather than the expected 6 days, to reach the histological mid-secretory phase. This is not a delay and is also seen in fertile patients. The new analysis method used is superior to that using Noyes criteria alone and provides a better basis for determining conditions for optimal timing of embryo transfers.


Subject(s)
Endometrium , Menstrual Cycle , Biopsy , Embryo Implantation , Female , Humans , Ovulation , Progesterone , Receptors, Progesterone/genetics
6.
Appl Opt ; 58(36): 9876-9882, 2019 Dec 20.
Article in English | MEDLINE | ID: mdl-31873633

ABSTRACT

During the last decade, the shortwave infrared (SWIR) spectral range has become a contender for night vision applications. For this application, it is necessary to compare SWIR and visible (VIS) sensor performance, which requires knowledge of illumination in these two ranges. Fraunhofer Institute of Optronics, System Technologies, and Image Exploitation initiated comparative long-time assessment of VIS and SWIR illumination including cloud coverage in 2019. A first analysis based on three months of operation is presented, showing preliminary results of the VIS/SWIR comparison, highlighting the problems of artificial light influence, and connecting the illumination to environmental effects.

7.
J Phys Chem A ; 117(39): 9975-84, 2013 Oct 03.
Article in English | MEDLINE | ID: mdl-23621684

ABSTRACT

The method of laser-induced reaction (LIR) is used to obtain high-resolution IR spectra of CH2D(+) in collision with n-H2 at a nominal temperature of 14 K. For this purpose, a home-built optical parametric oscillator (OPO), tunable in the range of 2500-4000 cm(-1), has been coupled to a 22-pole ion trap apparatus. In total, 112 lines of the ν1 and ν4 bands have been recorded. A line list is inferred from a careful analysis of the shape of the LIR signal. Line positions have been determined to an accuracy of 1 × 10(-4) cm(-1), allowing for the prediction of pure rotational transitions with MHz accuracy. In addition, an IR-THz double-resonance LIR depletion technique is applied to H2D(+) to demonstrate the feasibility for pure rotational spectroscopy with LIR.

8.
J Phys Chem A ; 117(16): 3332-9, 2013 Apr 25.
Article in English | MEDLINE | ID: mdl-23477539

ABSTRACT

We report on the detection of the (10(0)1) ← (00(0)0) vibrational band of gas-phase C3 and the two of its mono (13)C substituted isotopologs in the infrared region around 3200 cm(-1). Additionally, the associated hot band (11(1)1) ← (01(1)0) has been assigned for the parent isotopolog. Spectra have been recorded using a supersonic jet spectrometer with a laser ablation source in combination with a continuous-wave optical parametric oscillator as radiation source. High-level quantum-chemical ab initio calculations have been performed and used to assist the assignment. A combined fit for the vibrational states of C3 found in this study has been done together with previously reported high-resolution data to increase the accuracy of the molecular parameters, especially for the ground state. The vibrational energies are 3260.126, 3205.593, and 3224.751 cm(-1) for the (10(0)1) state of C3, (12)C(13)C(12)C, and (13)C(12)C(12)C, respectively. The (11(1)1) state of C3 has been found to be at 3330.509 cm(-1).

9.
Int J Cardiol ; 167(1): 114-20, 2013 Jul 15.
Article in English | MEDLINE | ID: mdl-22206633

ABSTRACT

INTRODUCTION: Complete occlusion of the pulmonary veins (PV) is crucial for successful PV isolation. While two different sizes of cryoballoons (23 and 28 mm) are available, complete occlusion is not always achieved in any given PV. We investigated the role of PV ostial anatomy during cryoballoon PV occlusion grading and atrial fibrillation (AF) recurrence rate. METHODS: PV ostial diameter was analyzed in 168 consecutive patients (111 men, 61 ± 10 years, 124 paroxysmal (px) and 44 persistent AF) using cardiac computed tomography (CT) prior to procedure. The ovality index at the PV ostial level was calculated in any given PV. During follow-up, 7-day holter monitors were performed at 1, 3, 6, 9, 12, 18 and 24 months post-ablation. RESULTS: The success rate at 12 ± 6 months follow-up was 69% including a 3-month blanking period (px AF: 66%; persistent AF 77%). The ovality index of the left-sided PVs was significantly larger ("more oval") than that of the right-sided PVs (p<0.001). An optimized PV occlusion in all individual PVs (complete occlusion, grading 4/4) was achieved during ablation in 49% of patients with AF recurrence and in 73% of patients without AF recurrence (p=0.004). Patients with AF recurrence had "more oval" left-sided PVs compared to patients free from AF recurrence (LSPV 0.40 ± 0.2 vs. 0.33 ± 0.2; p=0.04 and LIPV 0.41 ± 0.3 vs. 0.32 ± 0.2; p=0.03), whereas no significant association was found for right sided PVs. CONCLUSION: The ostial PV anatomy seems to have an important impact on clinical outcome and should be considered when planning and performing cryoballoon AF ablation procedures.


Subject(s)
Atrial Fibrillation/diagnostic imaging , Atrial Fibrillation/surgery , Catheter Ablation/methods , Cryosurgery/methods , Pulmonary Veins/diagnostic imaging , Pulmonary Veins/surgery , Aged , Angioplasty, Balloon, Coronary/methods , Female , Follow-Up Studies , Humans , Male , Middle Aged , Radiography , Treatment Outcome
10.
Rev Sci Instrum ; 83(9): 093110, 2012 Sep.
Article in English | MEDLINE | ID: mdl-23020365

ABSTRACT

A mid-infrared spectrometer consisting of a high power optical parametric oscillator, a frequency comb, and a cold ion trap is described and characterized. The idler frequency at 3 µm is measured accurately by analyzing the pump and signal beat frequencies with the comb. This is done via two spectrum analyzers, allowing for a wide and continuous scanning ideal for spectroscopy of cold molecules with unknown spectra. The potential of this approach is demonstrated by measuring a ro-vibrational line of CH(5)(+) in a 22-pole ion trap via action spectroscopy of only several thousand cold ions. The current setup limits the precision of the line center frequency determination to some 100 kHz with ample room for future improvements. Following this approach, ground state combination differences of molecular ions can be predicted in order to identify them in astronomical objects.

11.
Clin Res Cardiol ; 101(10): 777-85, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22484346

ABSTRACT

AIMS: Cryoballoon technology is a promising technique in paroxysmal atrial fibrillation (AF) ablation. However, success rates in patients with persistent AF have not been convincing. There is a trend toward performing more extensive procedures that are referred to as 'pulmonary vein isolation plus.' To combine pulmonary vein isolation (PVI) and antral substrate modification, we used both the 23-mm and 28-mm cryoballoon in a single approach in patients with persistent AF. METHODS AND RESULTS: 33 consecutive patients (26 men, age 60 ± 10 years, LA size 44 ± 5 mm) with persistent AF were prospectively included. All patients underwent the "double balloon strategy:" at least two applications at each pulmonary vein (PV) using the smaller 23-mm balloon to isolate the PV at the ostial level plus at least one additional freeze by the 28-mm balloon at the wide PV antral level. 7-day Holter monitors were performed during follow-up at 1, 3, 6, 9, 12, 18 and 24 months post-ablation. 131 of 133 PVs were targeted and isolated (98.4 %). A mean of 14 ± 2 cryoballoon applications per patient or 3.5 ± 1.5 applications per vein were performed. After a single procedure and mean follow-up of 15 ± 3 months, 69.7 % of patients remained in sinus rhythm (3-month blanking period). There were no major complications. CONCLUSIONS: In persistent AF, the "double balloon strategy;" combining the small and large cryoballoon allowed ostial PV isolation followed by antral cryoablation is feasible, safe and associated with a favorable outcome.


Subject(s)
Angioplasty, Balloon/methods , Atrial Fibrillation/therapy , Catheter Ablation/methods , Cryotherapy/methods , Aged , Angioplasty, Balloon/adverse effects , Atrial Fibrillation/physiopathology , Electrocardiography, Ambulatory , Feasibility Studies , Female , Follow-Up Studies , Humans , Male , Middle Aged , Pilot Projects , Prospective Studies , Time Factors , Treatment Outcome
12.
J Psychiatr Res ; 45(12): 1585-92, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21803373

ABSTRACT

Polysomnograhic (PSG) studies in Alzheimer's disease (AD) show REM sleep abnormalities, which may be indicative for the deterioration of cholinergic pathways and probably closely linked to declarative memory impairment. To clarify the specificity of the association between sleep and cognitive impairment in dementia, we compared AD patients with patients suffering from frontotemporal dementia (FTD) with regard to PSG and neuropsychological variables. 15 AD and 6 FTD patients underwent polysomonography and a neuropsychological battery (CERAD-NB). Group differences (age: AD > FTD; education level: AD < FTD) were considered as covariates. Polysomnography revealed a trend towards increased REM latency and reduced REM sleep in AD, as well as a decrease of stage 2 sleep, however, at least partly due to effects of age. Declarative memory was more impaired in AD than in FTD, but this difference disappeared when adjusted for covariates. While no relationship was found between REM sleep and CERAD-NB parameters, strong positive correlations between stage 2 sleep and declarative memory measures were observed, which were also detectable when analyzing both groups separately. Based on these results we conclude that REM sleep alterations may be specific for AD, distinguishable from other dementia diagnoses, whereas NonREM stage 2 sleep may be related to declarative memory formation in dementia independent of subtype.


Subject(s)
Alzheimer Disease/complications , Cognition Disorders/diagnosis , Cognition Disorders/etiology , Frontotemporal Dementia/complications , Polysomnography , Aged , Analysis of Variance , Chi-Square Distribution , Female , Humans , Male , Middle Aged , Neuropsychological Tests , Psychiatric Status Rating Scales
13.
Psychopharmacology (Berl) ; 217(3): 323-9, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21484237

ABSTRACT

OBJECTIVE: Several studies have shown that glucocorticoids can impair declarative memory retrieval and working memory (WM) performance. The aim of the present study was to investigate the impact of a high dose of hydrocortisone on WM, as well as to examine the effects of cortisol suppression via treatment with a high dose of dexamethasone (DEX). We hypothesized that hydrocortisone treatment results in an impaired cognitive function compared with placebo. We further expected that dexamethasone treatment is also followed by cognitive impairment, due to the hypothesis that very low levels of cortisol are also associated with alterations in memory performance. METHODS: In a placebo-controlled study with a within-subject design, 16 healthy volunteers received placebo or 120 mg of hydrocortisone (two boluses of 60 mg) directly before neuropsychological testing or 4 mg of DEX the day before testing. RESULTS: We did not find any effect of hydrocortisone on WM and cognitive flexibility, even though cortisol levels were high at the time of testing. Furthermore, we did not find any effect of DEX treatment on WM and reaction time in a cognitive flexibility test. However, cognitive flexibility was negatively correlated with adrenocorticotropin (ACTH) in the DEX condition. CONCLUSIONS: Our results found no clear effect of hydrocortisone and dexamethasone treatment on WM. These results emphasize the need for further research on the association between hypothalamic-pituitary-adrenal axis activity and cognition. These studies should investigate the hypotheses of dose-dependent associations in more detail and should also include analyses on ACTH and cognition.


Subject(s)
Cognition/drug effects , Dexamethasone/adverse effects , Hydrocortisone/adverse effects , Memory, Short-Term/drug effects , Adult , Dexamethasone/administration & dosage , Dexamethasone/blood , Dose-Response Relationship, Drug , Double-Blind Method , Female , Humans , Hydrocortisone/administration & dosage , Hydrocortisone/blood , Hypothalamo-Hypophyseal System/drug effects , Male , Middle Aged , Neuropsychological Tests , Pituitary-Adrenal System/drug effects
14.
Phytother Res ; 24(10): 1549-53, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20878709

ABSTRACT

Plant extracts such as Hypericum perforatum and Pycnogenol have been tested as alternatives to the classical ADHD drugs. It has been possible to describe neuroprotective effects of such plant extracts. A reduction of ADHD symptoms could be shown in clinical studies after the application of Pycnogenol, which is a pine bark extract. The impacts of the standardized herbal extracts Hypericum perforatum, Pycnogenol and Enzogenol up to a concentration of 5000 ng/mL on cell survival and energy metabolism in human SH-SY5Y neuroblastoma cells has been investigated in the present examination. Hypericum perforatum significantly decreased the survival of cells after treatment with a concentration of 5000 ng/mL, whereas lower concentrations exerted no significant effects. Pycnogenol( induced a significant increase of cell survival after incubation with a concentration of 32.25 ng/mL and a concentration of 250 ng/mL. Other applied concentrations of Pycnogenol failed to exert significant effects. Treatment with Enzogenol did not lead to significant changes in cell survival.Concerning energy metabolism, the treatment of cells with a concentration of 5000 ng/mL Hypericum perforatum led to a significant increase of ATP levels, whereas treatment with a concentration of 500 ng/mL had no significant effect. Incubation of cells with Pycnogenol and Enzogenol exerted no significant effects.None of the tested substances caused any cytotoxic effect when used in therapeutically relevant concentrations.


Subject(s)
Cell Survival/drug effects , Energy Metabolism , Flavonoids/pharmacology , Hypericum/chemistry , Plant Extracts/pharmacology , Quercetin/analogs & derivatives , Attention Deficit Disorder with Hyperactivity/drug therapy , Cell Line, Tumor , Humans , Phytotherapy , Quercetin/pharmacology
15.
Expert Rev Neurother ; 10(7): 1101-15, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20586691

ABSTRACT

Sleep deprivation (SD) is a powerful antidepressant treatment that shows antidepressant responses within hours in 40-60% of depressed patients. In more than 80% of responders to SD, a relapse into depression occurred after the recovery night. In addition, it serves as an excellent tool to examine the neurobiological disturbance of depression and may profoundly contribute to the development of new specific and more rapidly acting antidepressants. The reason why SD works and relapses occur is still unclear. A key to solve this problem is to include the current knowledge about the neurobiological disturbance of depression in research, with a focus on neurobiological aspects of sleep and SD (sleep EEG, neuroendocrinology, neurochemistry and chronobiology). Based on findings from these different areas, different strategies to stabilize the antidepressant effect of SD have been applied. This article provides an overview of clinical and neurobiological responses related to SD in depression.


Subject(s)
Depression/therapy , Sleep Deprivation , Depression/physiopathology , Humans , Sleep/physiology
16.
J Neural Transm (Vienna) ; 117(6): 793-7, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20467764

ABSTRACT

Oxidative DNA damage as one sign of reactive oxygen species induced oxidative stress is an important factor in the pathogenesis of various psychiatric disorders. Altered levels of DNA base damage products as well as the expression of the main repair enzyme 8-hydroxyguanine glycosylase 1 have been described. The aim of the present study was to examine the effects of drugs (amphetamine, methylphenidate and atomoxetine) used in the treatment of attention deficit-hyperactivity disorder on the expression of this enzyme via reverse transcriptase-polymerase chain reaction in human neuroblastoma SH-SY5Y and human monocytic U-937 cells at concentrations of 50, 500 and 5,000 ng/ml. We observed decreased expression of this enzyme for all applied substances. In U-937 cells, the significance level was reached after treatment with 5,000 ng/ml amphetamine as well as after treatment with 50, 500 and 5,000 ng/ml atomoxetine. Incubation of SH-SY5Y cells with 50 and 5,000 ng/ml amphetamine and 5,000 ng/ml methylphenidate led to significant decreases of 8-hydroxyguanine glycosylase 1. As a positive correlation between the expression of 8-hydroxyguanine glycosylase 1 and the level of oxidative DNA damage products has been described, we accordingly consider these substances (amphetamine, methylphenidate and atomoxetine) to possibly play a protective role in this process.


Subject(s)
Adrenergic Uptake Inhibitors/pharmacology , Central Nervous System Stimulants/pharmacology , DNA Glycosylases/metabolism , Gene Expression Regulation, Enzymologic/drug effects , Propylamines/pharmacology , Amphetamine/pharmacology , Atomoxetine Hydrochloride , Cell Line , DNA Glycosylases/genetics , Dose-Response Relationship, Drug , Humans , Methylphenidate/pharmacology , Monocytes/cytology , Neuroblastoma , RNA, Messenger/metabolism
17.
J Psychiatr Res ; 43(16): 1253-61, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19467668

ABSTRACT

Several studies reported a decreased pain sensitivity in patients with depression, but the underlying neurobiological mechanisms of this phenomenon are unclear. While there is extensive evidence that the serotoninergic system plays a key role in pain modulation, especially in pain inhibitory mechanisms via descending pathways, as well as in the pathophysiology of depression, no study so far has examined its potential relevance in mediating the alteration of pain processing. The present study addresses the question of whether indices of serotoninergic dysfunction, as investigated by a neuroendrocine challenge paradigm, are related to pain sensitivity. Nineteen drug-free inpatients with unipolar major depression underwent a neuroendocrine challenge test by measuring cortisol and prolactin in response to intravenously administered clomipramine (12.5mg). Heat/cold pain thresholds, warmth/cold detection thresholds, measures of current pain complaints and mood were assessed the day before and three day after challenge procedure. When patients were classified in subgroups based on a median split of their cortisol response values, the low-responsive group showed significantly elevated heat pain thresholds and nearly significantly elevated cold pain thresholds compared to the high-responsive group. No such group differences were found with regard to somatosensory thresholds, measures of pain complaints and mood. Subgrouping on the basis of prolactin responsiveness did not reveal significant differences in any parameter. In summary, a decreased pain sensitivity was demonstrated in patients characterized by a reduced neuroendocrine responsiveness to clomipramine, suggesting an involvement of serotoninergic dysfunction underlying altered pain perception in depression.


Subject(s)
Antidepressive Agents, Tricyclic/pharmacology , Clomipramine/pharmacology , Depressive Disorder, Major/physiopathology , Hyperalgesia/physiopathology , Neurosecretory Systems/drug effects , Pain Threshold/physiology , Serotonin/metabolism , Antidepressive Agents, Tricyclic/therapeutic use , Area Under Curve , Chi-Square Distribution , Clomipramine/therapeutic use , Depressive Disorder, Major/drug therapy , Humans , Hydrocortisone/metabolism , Hyperalgesia/psychology , Lectins, C-Type/metabolism , Pain Measurement/methods , Pain Threshold/drug effects , Physical Stimulation/methods , Radioimmunoassay/methods , Severity of Illness Index
18.
J Psychiatr Res ; 43(7): 711-20, 2009 Apr.
Article in English | MEDLINE | ID: mdl-18930473

ABSTRACT

While data dealing with neurobiological effects of sleep deprivation (SD) are mainly restricted to the acute effects of a single night, only few studies have investigated mid-term effects after repeated SD. We therefore examined the clinical and hormonal characteristics of depressive patients before and after serial SD to determine potential sustained effects, focusing especially on serotoninergic functions. One tool to investigate serotoninergic dysfunction in depression is the use of serotoninergic agents to stimulate hormonal secretion, which is assumed to normalize during a clinically effective therapy. Eighteen drug-free inpatients with unipolar major depression received cognitive-behavioral treatment for three weeks and - according to a randomized control design - additional SD therapy (six nights of total SD within three weeks, separated by nights of recovery sleep) or no SD therapy (control group). Serotoninergic function was assessed by measuring cortisol and prolactin in response to intravenously administered clomipramine (12.5mg) before and after the treatment period. The post-treatment challenge test was performed three days after the last SD night. Apart from of a transient overnight improvement of mood induced by SD, both groups showed a comparable clinical course during the three-week treatment period. Compared to the control group, the SD-treated patients exhibited significantly decreased pre-stimulation cortisol levels and significantly increased cortisol responses to clomipramine, whereas no treatment effects were observed for prolactin. In conclusion, our findings suggest that the mid-term effects of serial SD therapy lead to a normalization of serotoninergic dysfunction, although an obvious impact on clinical symptoms was not detected.


Subject(s)
Affect , Behavior Therapy , Cognitive Behavioral Therapy , Depressive Disorder, Major/physiopathology , Depressive Disorder, Major/therapy , Hydrocortisone/blood , Prolactin/blood , Sleep Deprivation/physiopathology , Adult , Affect/drug effects , Analysis of Variance , Antidepressive Agents, Tricyclic/administration & dosage , Antidepressive Agents, Tricyclic/therapeutic use , Clomipramine/administration & dosage , Clomipramine/therapeutic use , Combined Modality Therapy/methods , Depressive Disorder, Major/diagnosis , Depressive Disorder, Major/psychology , Enzyme-Linked Immunosorbent Assay , Female , Humans , Injections, Intravenous , Inpatients , Male , Psychiatric Status Rating Scales , Sleep Deprivation/psychology , Time Factors , Treatment Outcome
19.
J Psychiatr Res ; 43(8): 818-23, 2009 May.
Article in English | MEDLINE | ID: mdl-19101687

ABSTRACT

Antipsychotics are known to alter antioxidant activities in vivo. Therefore, the aim of the present study was to examine in the human neuroblastoma SH-SY5Y cell line the impact of a typical (haloperidol) and an atypical (quetiapine) antipsychotic on the expression of genes encoding the key enzymes of the antioxidant metabolism (Cu, Zn superoxide dismutase; Mn superoxide dismutase; glutathione peroxidase; catalase) and enzymes of the glutathione metabolism (gamma-glutamyl cysteine synthetase, glutathione-S-transferase, gamma-glutamyltranspeptidase, glutathione reductase). The cells were incubated for 24h with 0.3, 3, 30 and 300microM haloperidol and quetiapine, respectively; mRNA levels were measured by polymerase chain reaction. In the present study, we observed mostly significant decreases of mRNA contents. With respect to the key pathways, we detected mainly effects on the mRNA levels of the hydrogen peroxide detoxifying enzymes. Among the enzymes of the glutathione metabolism, glutathione-S-transferase- and gamma-glutamyltranspeptidase-mRNA levels showed the most prominent effects. Taken together, our results demonstrate a significantly reduced expression of genes encoding for antioxidant enzymes after treatment with the antipsychotics, haloperidol and quetiapine.


Subject(s)
Antioxidants/metabolism , Antipsychotic Agents/pharmacology , Dibenzothiazepines/pharmacology , Gene Expression Regulation, Enzymologic/drug effects , Gene Expression Regulation, Neoplastic/drug effects , Haloperidol/pharmacology , Neuroblastoma/metabolism , RNA, Messenger/metabolism , Catalase/biosynthesis , Catalase/genetics , Catalase/metabolism , Cell Line, Tumor , Down-Regulation/drug effects , Glutamate-Cysteine Ligase/metabolism , Glutathione Peroxidase/metabolism , Glutathione Reductase/metabolism , Glutathione Transferase/metabolism , Humans , Quetiapine Fumarate , Reverse Transcriptase Polymerase Chain Reaction , Superoxide Dismutase/metabolism
20.
J Psychiatr Res ; 43(6): 620-6, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19110264

ABSTRACT

OBJECTIVE: To explore the impact of premorbid and baseline body mass indices (BMIs) as well as BMI of patient's parents and associated variables on the prediction of antipsychotic-induced body weight gain. METHODS: Retrospective/cross-sectional data of 65 patients receiving clozapine, olanzapine and/or risperidone were assessed according to a systematic categorization of the long-term (7.3+/-9.2 years) weight course and evaluated using descriptive, explorative correlation and regression analyses. RESULTS: Increased values of parents' BMI (p=0.041) and patients' BMI at premorbid stage (p=0.039) and prior to first antipsychotic treatment (p=0.032) as well as female gender (p=0.012), younger age (p=0.005) and non-smoking (p=0.047) have the most predictive value on body weight gain under antipsychotic treatment including pre-treatment with typical antipsychotics. Weight gain under atypical antipsychotics (pre-treatment excluded) is predicted by an increased premorbid BMI (p=0.019). Conversely, a low BMI prior to first antipsychotic treatment predicts a higher acceleration of BMI change (p=0.008) in vulnerable individuals, but not total BMI change itself. Furthermore, a diagnosis of a schizophrenia spectrum disorder showed a trend towards the prediction of an increased atypical DeltaBMI (p=0.067), possibly due to a longer treatment duration with atypical antipsychotics (p<0.001). DISCUSSION: The study indicates increased parents' BMI and patients' premorbid BMI, female gender, younger age and - as a trend - the diagnosis of a schizophrenia spectrum disorder to be predictors for antipsychotic-induced body weight gain involving atypical antipsychotics. Data contribute to the assumption of a strong impact of predispositional factors on weight gain, besides treatment-related factors.


Subject(s)
Antipsychotic Agents/adverse effects , Body Mass Index , Weight Gain/drug effects , Adolescent , Adult , Age Factors , Analysis of Variance , Antipsychotic Agents/therapeutic use , Benzodiazepines/adverse effects , Benzodiazepines/therapeutic use , Body Weight/drug effects , Clozapine/adverse effects , Clozapine/therapeutic use , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Olanzapine , Parents , Retrospective Studies , Risk Factors , Risperidone/adverse effects , Risperidone/therapeutic use , Sex Factors , Smoking , Time Factors , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...